Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer
AuthorsMorgan, Robert David
Mitchell, Claire L
Clamp, Andrew R
Jayson, Gordon C
AffiliationDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
MetadataShow full item record
AbstractBackground: Malignant bowel obstruction (MBO) is a common cause of morbidity and mortality in women diagnosed with ovarian cancer. Earlier detection of MBO may improve patient outcomes. There are currently no screening tools to assist detection. Aim: We report a screening questionnaire that can be used to detect MBO, and how the severity score for key clinical symptoms correlate with radiological evidence of MBO from ovarian cancer. Design: A case-control study in which patients with relapsed, metastatic ovarian cancer were asked to answer 10 questions related to key clinical symptoms associated with intestinal obstruction. The study group included women with CT-confirmed MBO, whereas the control group had no evidence of MBO. Patients scored each question according to severity from 1 (least severe) to 5 (most severe). Setting/participants: Between 1 June and 31 December 2016, 37 women completed the screening questionnaire. Results: Patients in the study group (n=17) reported significantly higher (ie, more severe) scores for abdominal pain, nausea, vomiting and constipation. In contrast, differences in severity scores between groups did not differ significantly in response to questions regarding abdominal swelling, borborygmi, diarrhoea or loss of appetite. All patients in the study group more frequently stated that their symptoms had deteriorated within the 2 months prior to completing the questionnaire. Conclusion: Here we report the key clinical symptoms associated with radiologically-confirmed MBO in relapsed, metastatic ovarian cancer. We recommend healthcare practitioners focus on these specific symptoms during patient consultations in order to improve risk stratification of MBO.
CitationMorgan RD, Stamatopoulou S, Mescallado N, Saunders G, Welch R, Mitchell C, et al. Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer. ESMO Open. 2019; 4(2):e000463.
- Malignant Bowel Obstruction in Relapsed Ovarian Cancer With Peritoneal Carcinomatosis: An Occlusive State.
- Authors: Martinez Castro P, Vargas L, Mancheño A, Martín Utrilla S, Pascual F, Romero I, Zorrero C, Bosch JM, Poveda A, Minig L
- Issue date: 2017 Sep
- Oral water soluble contrast for malignant bowel obstruction.
- Authors: Syrmis W, Richard R, Jenkins-Marsh S, Chia SC, Good P
- Issue date: 2018 Mar 7
- Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?
- Authors: Hoppenot C, Peters P, Cowan M, Moore ED, Hurteau J, Lee NK, Yamada SD
- Issue date: 2019 Jul
- Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer.
- Authors: Lee YC, Jivraj N, Wang L, Chawla T, Lau J, Croke J, Allard JP, Stuart-McEwan T, Nathwani K, Bowering V, Karakasis K, O'Brien C, Shlomovitz E, Ferguson SE, Buchanan S, Ng P, Cyriac S, Tinker L, Dhani N, Oza AM, Lheureux S
- Issue date: 2019 Dec
- Oral water-soluble contrast (Gastrografin) for malignant bowel obstruction: open label pilot study.
- Authors: Wan Bahrum WFIB, Hardy J, Foster K, Good P
- Issue date: 2022 Jan 19